Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04183166 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

A Phase 1 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Transgene.

Active
Registry status
Phase 1
Development phase
80
Enrollment target
14
Study locations

NCT04183166 is a Phase 1 study of Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by Transgene. The registered enrollment target is 80 participants, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (52% lower). The trial reports 14 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04183166, a Phase 1 study of Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by Transgene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
14
Study locations

Study Summary

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Conditions Studied

Squamous Cell Carcinoma of Head and Neck

Interventions

  • DRUG TG4050

Study Locations (14)

Other

  • Hôpital Saint André - CHU de Bordeaux - Bordeaux
  • Hôpital de la Timone - Marseille
  • Institut Curie - Paris
  • IUCT Toulouse - Toulouse
  • Institut Gustave Roussy - Villejuif
  • Hospital Universitari Vall d Hebrón - Barcelona
  • Institut Català d Oncologia - Hospital Duran i Reynals - Barcelona
  • Hospital Clínico San Carlos - Madrid
  • Hospital Universitario La Paz - Madrid
  • Hospital Regional Universitario de Málaga - Hospital Civil - Málaga
  • Complejo Hospitalario Universitario de Santiago - Santiago de Compostela
  • NHS Clatterbridge Cancer Center - Liverpool
  • Aintree University Hospital NHS Fondation Trust - Liverpool

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2019-12-12
Est. Completion 2031-12-30
Phase Phase 1

Sponsor

Transgene

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04183166

The ClinicalTrials.gov registry entry for NCT04183166 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (52% lower). The listed sponsor is Transgene, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which TG4050 is the first listed.

NCT04183166 reports 14 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.

Frequently Asked Questions

What is clinical trial NCT04183166 about?

NCT04183166 is a clinical study titled "A Clinical Trial Evaluating TG4050 in Head and Neck Cancer". This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

What is the current status of trial NCT04183166?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2019-12-12. Estimated completion is 2031-12-30.

What conditions does trial NCT04183166 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT04183166?

The interventions under investigation include: TG4050 (DRUG).

Who is sponsoring clinical trial NCT04183166?

This trial is sponsored by Transgene, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04183166 being conducted?

This trial has 14 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.